jerald radich
jerald radich
Verified email at fredhutch.org
TitleCited byYear
Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia
BJ Druker, F Guilhot, SG O'Brien, I Gathmann, H Kantarjian, N Gattermann, ...
New England Journal of Medicine 355 (23), 2408-2417, 2006
35652006
European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013
M Baccarani, MW Deininger, G Rosti, A Hochhaus, S Soverini, ...
Blood 122 (6), 872-884, 2013
15772013
Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet
M Baccarani, J Cortes, F Pane, D Niederwieser, G Saglio, J Apperley, ...
Journal of clinical oncology 27 (35), 6041, 2009
14922009
Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects
PA McSweeney, D Niederwieser, JA Shizuru, BM Sandmaier, AJ Molina, ...
Blood 97 (11), 3390-3400, 2001
14522001
Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia
TP Hughes, J Kaeda, S Branford, Z Rudzki, A Hochhaus, ML Hensley, ...
New England Journal of Medicine 349 (15), 1423-1432, 2003
14092003
Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL …
T Hughes, M Deininger, A Hochhaus, S Branford, J Radich, J Kaeda, ...
Blood 108 (1), 28-37, 2006
12382006
Early detection: The case for early detection
R Etzioni, N Urban, S Ramsey, M McIntosh, S Schwartz, B Reid, J Radich, ...
Nature reviews cancer 3 (4), 243, 2003
10992003
Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia
A Hochhaus, SG O'brien, F Guilhot, BJ Druker, S Branford, L Foroni, ...
Leukemia 23 (6), 1054, 2009
9502009
The role of FLT3 in haematopoietic malignancies
DL Stirewalt, JP Radich
Nature Reviews Cancer 3 (9), 650, 2003
9132003
Massively parallel digital transcriptional profiling of single cells
GXY Zheng, JM Terry, P Belgrader, P Ryvkin, ZW Bent, R Wilson, ...
Nature communications 8, 14049, 2017
8932017
International Randomized Study of Interferon vs STI571 (IRIS) 8-Year Follow up: sustained survival and low risk for progression or events in patients with newly diagnosed …
M Deininger, SG O'Brien, F Guilhot, JM Goldman, A Hochhaus, ...
Blood 114 (22), 1126-1126, 2009
7312009
Chronic graft-versus-host disease and other late complications of bone marrow transplantation.
KM Sullivan, E Agura, C Anasetti, F Appelbaum, C Badger, S Bearman, ...
Seminars in hematology 28 (3), 250-259, 1991
7221991
Bone marrow transplants from unrelated donors for patients with chronic myeloid leukemia
JA Hansen, TA Gooley, PJ Martin, F Appelbaum, TR Chauncey, RA Clift, ...
New England Journal of Medicine 338 (14), 962-968, 1998
6981998
Lin28 promotes transformation and is associated with advanced human malignancies
SR Viswanathan, JT Powers, W Einhorn, Y Hoshida, TL Ng, S Toffanin, ...
Nature genetics 41 (7), 843, 2009
6862009
Prevalence and prognostic significance of Flt3 internal tandem duplication in pediatric acute myeloid leukemia
S Meshinchi, WG Woods, DL Stirewalt, DA Sweetser, JD Buckley, TK Tjoa, ...
Blood 97 (1), 89-94, 2001
5662001
Gene expression changes associated with progression and response in chronic myeloid leukemia
JP Radich, H Dai, M Mao, V Oehler, J Schelter, B Druker, C Sawyers, ...
Proceedings of the National Academy of Sciences 103 (8), 2794-2799, 2006
5402006
Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of …
TP Hughes, A Hochhaus, S Branford, MC Müller, JS Kaeda, L Foroni, ...
Blood 116 (19), 3758-3765, 2010
5212010
FLT3, RAS, and TP53 mutations in elderly patients with acute myeloid leukemia
DL Stirewalt, KJ Kopecky, S Meshinchi, FR Appelbaum, ML Slovak, ...
Blood 97 (11), 3589-3595, 2001
4802001
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial
H Kantarjian, R Pasquini, N Hamerschlak, P Rousselot, J Holowiecki, ...
Blood 109 (12), 5143-5150, 2007
4752007
Nilotinib is effective in patients with chronic myeloid leukemia in chronic phase after imatinib resistance or intolerance: 24-month follow-up results
HM Kantarjian, FJ Giles, KN Bhalla, J Pinilla-Ibarz, RA Larson, ...
Blood 117 (4), 1141-1145, 2011
3852011
The system can't perform the operation now. Try again later.
Articles 1–20